3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

CryptoAlerta — análise de criptomoedas e mercado em tempo real